Sameer Bansilal

Dr. Sameer Bansilal is a clinician and investigator with a broad range of expertise in cardiovascular medicine and outcomes research on a global scale. Dr. Bansilal is currently an Assistant Professor of Medicine at the Icahn School of Medicine at Mount Sinai and an Attending Physician in the Mount Sinai Cardiovascular Institute. Over the last decade, he has trained as a clinical trialist and a global health outcomes researcher at Mount Sinai, NYU, Brigham and Women’s Hospital and the Harvard School of Public Health. During this time, he has had the opportunity to work on various NIH and pharmaceutical sponsored clinical trials and global health projects. He has served as a co-investigator for the FREEDOM trial (NIH-UO1; 1900 patients), PEGASUS-TIMI 54 (21,000 patients worldwide) and DECLARE-TIMI 58 (17,150 patients worldwide). He has served as the medical lead for the Grenada Heart Project, a cardiovascular risk factor survey of 2,827 subjects in the Caribbean Islands of Grenada and as a co-investigator for the High-risk plaque project (6000 patients) with multimodal imaging for prediction of cardiovascular events. Finally, he is currently serving as the medical lead on the Polypill evaluation studies in the United States to look at whether providing a fixed-dose combination improves adherence and is cost-effective. Dr. Bansilal’s clinical and research interests center on therapies for coronary disease, diabetes and asymptomatic patients with various heart disorders in global populations. His special interests include advanced trial design and trial methodology.